ArticleCancer science2026
Orthotopic Esophageal Cancer Xenograft Model in Immunosuppressed Microminipigs for Near-Infrared Fluorescence Endoscopy.
Article in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal squamous cell carcinoma (ESCC) often presents as flat lesions difficult to detect with conventional endoscopy, leading to poor prognosis. To overcome this, we developed a near-infrared (NIR) molecular imaging strategy using an epidermal growth factor receptor (EGFR)-targeted antibody and established a novel orthotopic microminipig (MMP) model for translational evaluation. First, cetuximab was labeled with Alexa Fluor 680 (AF680) and validated in vitro for specific binding. Among five ESCC cell lines profiled for proliferation and antigen density, KYSE410 was selected for in vivo studies due to its optimal balance of these factors. In mouse xenografts, AF680-cetuximab tumor fluorescence peaked at 96 h, achieving high signal-to-noise ratios. Subsequently, to establish a clinically relevant large-animal platform, we optimized an immunosuppression protocol for MMPs. Through iterative testing, we determined that a combination of neonatal thymectomy and pharmacologic immunosuppression (tacrolimus, mycophenolate mofetil, and prednisolone), supplemented with antibiotics and proton-pump inhibitors, was essential to prevent rejection, sepsis, and gastric ulcers. This optimized regimen enabled stable orthotopic engraftment of human ESCC via endoscopic submucosal injection in the MMP esophagus. Using a custom-developed NIR fluorescence endoscope mimicking a clinical setting, we successfully visualized orthotopic tumors with clear margins at 96 h post-injection, subsequently confirmed by immunohistochemistry. In conclusion, AF680-cetuximab enables specific, high-contrast detection of ESCC. Furthermore, we report the first successful orthotopic engraftment of human cancer cells in immunosuppressed MMPs. This model provides a powerful platform for developing fluorescence-guided endoscopic diagnostics and theranostics for early-stage esophageal cancer, bridging the gap to future clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.